# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Keith Tapper initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform rating and ann...
RBC Capital analyst Gregory Renza reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and maintains $29 price ...
Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS™ study will b...
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price ta...
HC Wainwright & Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price t...
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30...